By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AmextaFinanceAmextaFinance
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
9
Notification Show More
Videos
Apple goes all in on custom chips
17 minutes ago
News
SoundHound: Strong Execution, Wild Valuation (Downgrade) (NASDAQ:SOUN)
4 hours ago
News
Trump looms large over Nobel Peace Prize
9 hours ago
News
US demands EU dismantle green regulations in threat to trade deal
10 hours ago
Videos
President Trump’s history with Fed Chair Powell, takeaways from the trading day
24 hours ago
Videos
How Digital Price Tags Are Changing Food Shopping
1 day ago
News
Lexeo Therapeutics, Inc. (LXEO) Update for LX2006 for the Treatment of Friedreich Ataxia
1 day ago
Videos
Fed Chair Jerome Powell’s speech from the Jackson Hole Economic Policy Symposium
2 days ago
Videos
Why U.S. 7-Elevens Are Adopting Japan’s Playbook
2 days ago
Aa
AmextaFinanceAmextaFinance
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
AmextaFinance > Investing > Apogee Therapeutics files for IPO
Investing

Apogee Therapeutics files for IPO

News Room
Last updated: 2023/06/23 at 8:09 AM
By News Room
Share
1 Min Read
SHARE

Apogee Therapeutics Inc. has filed for an initial public offering, according to a filing late Thursday. The biotech company did not provide the number of shares it intends to sell or a price range. Underwriters include ​Jefferies and TD Cowen, and the company said it would trade on the Nasdaq under the symbol APGE. The company, based in Waltham, Mass., seeks to develop “differentiated” treatments for atopic dermatitis, chronic obstructive pulmonary disease, and other illnesses with “high unmet need.” The company lost $12.5 million, or $2.51 a share, in the three months ended March 31, compared with losses of $4.3 million, or $4.19 a share, in the year-ago period. “Even if this offering is successful, we will require substantial additional capital to finance our operations in the future,” the company wrote as one of its risk factors in the prospectus.

Read the full article here

News Room June 23, 2023 June 23, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Apple goes all in on custom chips

Watch full video on YouTube

SoundHound: Strong Execution, Wild Valuation (Downgrade) (NASDAQ:SOUN)

This article was written byFollowWith combined experience of covering technology companies on…

Trump looms large over Nobel Peace Prize

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

US demands EU dismantle green regulations in threat to trade deal

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

President Trump’s history with Fed Chair Powell, takeaways from the trading day

Watch full video on YouTube

- Advertisement -
Ad imageAd image

You Might Also Like

Investing

Why Home Builders Are Bouncing Today—and Why Their Stocks Are Good Buys

By News Room
Investing

This Beaten-Down Industrial Stock Wants to Call America Home. Why It’s Time to Buy.

By News Room
Investing

These 8 Dividend Aristocrats Can Protect Your Portfolio in a Downturn

By News Room
Investing

Some Lenders Benefit From SBA’s Troubled Loan Program

By News Room
Investing

Social Security Is in Turmoil. Should You Lock In Benefits Now?

By News Room
Investing

Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast.

By News Room
Investing

Opinion: The stock-market selloff isn’t over yet. Here are 4 reasons why.

By News Room
Investing

With Trump’s tariffs paused, ‘Big Three’ automakers may race to build inventories

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

YOUR EMAIL HAS BEEN CONFIRMED.
THANK YOU!

Welcome Back!

Sign in to your account

Lost your password?